GBI Research identifies first-in-class as panacea for pharma companies
Posted: 14 June 2016 | Mandy Parrett, Editorial Assistant | No comments yet
In the face of the enormous costs involved in bringing a drug to market, pharmaceutical companies are increasingly aiming to develop first-in-class treatments to maximise return on this heavy burden, notes intelligence provider, GBI Research.


In the face of the enormous costs involved in bringing a drug to market, pharmaceutical companies are increasingly aiming to develop first-in-class treatments to maximise return on this heavy burden, notes intelligence provider, GBI Research.
The cost of bringing a single novel drug to market was estimated to be $2.6 billion in 2015, according to a recent report published by GBI Research.
GBI Research attribute onerous proof of superiority
The report states that the growth in drug research and development (R&D) costs appears to stem from an increased clinical failure rate and emphasis on proving superiority over comparator drugs.
Reduce preclinical failures with smarter off-target profiling
24 September 2025 | 15:00PM BST | FREE Webinar
Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.
What you’ll learn:
- Approaches for prioritizing follow-up studies and refining risk mitigation strategies
- How to interpret hit profiles from binding and functional assays
- Strategies for identifying organ systems at risk based on target activity modulation
- How to use visualization tools to assess safety margins and compare compound profiles
Register Now – It’s Free!
Dominic Trewartha, Managing Analyst for GBI Research, explains: “Due to the inherently limited life cycle of a patented drug and growing R&D costs as a percentage of net sales, the pharmaceutical industry has the highest R&D expenditure of all industries. As such, imperatives for pharmaceutical companies include reducing product development costs, maximising the annual product revenue, and optimising the life cycle of a drug, primarily by minimising the impact of the entry of generics.
“Together, these factors favour the inclusion of first-in-class pipeline products within a balanced pipeline portfolio.”
“Higher-risk programmes for innovative first-in-class products remain attractive and have led to some of the most clinically and commercially successful products over the past decade. Overall, ‘me-too’ drugs, which are structurally very similar to already-established drugs, have traditionally been highly commercially and clinically successful. These products continue to provide a well-established pathway for promising product developments due to a lower risk profile based on safer and more cost-effective incremental innovation.”
Trewartha concludes, however: “Some of the most successful products of the previous ten years have been first-in-class therapies, including Avastin (bevacizumab), Rituxan (rituximab), Herceptin (trastuzumab) and Gleevec (imatinib).”
“When 2015 FDA approvals are analysed, first-in-class products have far higher average projected sales than non-first-in-class products, indicating that this trend is set to continue in the future.”
“GBI Research believes that, despite the high risks involved in developing first-in-class products, pharmaceutical companies stand to earn high rewards through innovative development strategies.”
Related topics
Drug Discovery
Related organisations
GBI Research